ALCLS pivots to in vivo gene editing with two lead programs
ALCLS announced a shift to in vivo gene editing, advancing HEAL-101 and HEAL-201 for severe lipid disorders and extending its cash runway into 2028, while discontinuing internal cell therapy programs.